To our knowledge this is the first study investigating the influence of a strength training intervention—either alone or in combination with a nutritional supplement—on blood-based biomarkers of skeletal muscle degradation and growth as well as on MQ. Our results confirm that in women the MQ of lower extremities can be increased with elastic band resistance training even at an older age, whereas an additional supplementation with proteins and vitamins seems to be ineffective in exerting an additive effect. These changes were associated with an increase in follistatin and a decrease of activin A-to-follistatin ratio in the RT group while activin A levels were decreased only in the CT group.
Intervention effects on muscle quality
In this study the MQ of lower, but not that of upper extremities increased in both training groups (RT and RTS). As whole body skeletal muscle mass was used for the determination of both the MQ of upper and lower extremities, this observation might indirectly reflect the amelioration in chair stand test while handgrip strength was not affected by the strength training programme. Interestingly, the elastic band resistance training that we have used in our study seems to have more pronounced effects on functional performance than on strength as the arm lifting test and chair stand test showed improvements while handgrip strength and isokinetic peak torque measurements of knee extensors and flexors were not affected (Oesen et al.
2015). Furthermore, it is noteworthy that leg muscles suffer greater losses in strength and MQ than arm muscles with ageing (Frontera et al.
2000; Lynch et al.
1999). If we assume that our strength training programme was designed to challenge upper and lower extremities in a similar way, the adaptation capacity of the lower extremities to strength training could have been higher leading to more pronounced effects, although this is in contrast to another study showing that strength gains are higher for upper extremities as the muscles of the lower limbs are elicited more frequently and therefore, have a smaller potential to gain strength at older age (Sousa et al.
2011). Another factor that influences the determination of MQ is the lack of a uniform consensus which parameters to include in the calculation of MQ. While some studies including ours used whole body skeletal mass determined by BIA or DXA (Barbat-Artigas et al.
2012a; Schroeder et al.
2012), others determined skeletal muscle mass separately for upper and lower body by means of DXA or ultrasound (Kennis et al.
2014; Radaelli et al.
2014; Straight et al.
2015). In addition, several formulas are used to determine muscle mass by BIA, whereby it is recommended to use equations derived from a similar age group, which is what we ensured by using the formula of Janssen et al. (
2000). This formula has been developed in a multiethnic sample of 388 men and women, aged 18–86 years and includes age and gender as parameters. Furthermore, we checked the quality of BIA measurements by a parallel assessment of muscle mass by DXA in a smaller subgroup of the participants (
n = 45). Statistical analyses revealed a high correlation between DXA and BIA (
ρ = 0.847,
p < 0.001). The situation is even more complex for assessing strength or power as a variety of methods is available. Therefore, we decided to use chair stand test and handgrip test as suggested by Barbat-Artigas et al. (
2012b), but future studies evaluating the impact of these different methods on the assessment of MQ and on its influence on clinically relevant outcomes are highly recommended.
Intervention effects on blood-based parameters
Although performance parameters and MQ were increased in both training groups (RT and RTS), follistatin and the activin A-to-follistatin ratio were altered in the RT group only between T2 and T3 hinting to an adaptive delay in the response to training. Follistatin antagonizes myostatin and activin A and as such it is regarded as a positive regulator of muscle mass. Animal studies have shown that acute and chronic endurance exercises increase follistatin mRNA in the liver as well as in skeletal muscles (Hansen et al.
2011; Ziaaldini et al.
2015). Furthermore, serum levels of follistatin increased transiently during an ultra-marathon (Kerschan-Schindl et al.
2015). One of the rare studies investigating the influence of a comparable training setting (endurance or strength training) on follistatin levels in blood and muscle biopsies of young men has been published by Diel et al. (
2010). Similar to our study, follistatin remained unchanged in blood and biopsy samples after 3 months (Diel et al.
2010), but the authors did not investigate long-term effects of training making a conclusion difficult. Interestingly, follistatin was not altered in the RTS group. As the strength training programme was the same in both groups, this hints to some direct or indirect effect of the nutritional supplement containing proteins and vitamins on serum follistatin levels. It has been shown that circulating follistatin levels increase in response to a fasting period while activin A levels decrease (Vamvini et al.
2011). We have collected the blood after an overnight fast which was the same in all groups. The nutritional intake was assessed at T1 and T3. In addition, the nutritional supplementation resulted in an increased uptake of vitamin D and folic acid but not in protein being between 0.8 and 1.0 g/kg/day in the RTS group (Franzke et al.
2015a). Furthermore, plasma levels of vitamin B12 and folic acid in erythrocytes were enhanced due to supplementation (Franzke et al.
2015b). There is an ongoing discussion of whether antioxidant supplementation may blunt an exercise-induced training effect (Peternelj and Coombes
2011). With respect to functional performance we did not observe any differences between the RT and RTS group while we did in follistatin levels. In vitro studies have shown that there could be a direct effect of vitamin D administration on follistatin levels as 1α,25-dihydroxyvitamin D3 decreased follistatin in osteoblasts (Woeckel et al.
2013) but increased follistatin in myoblasts (Garcia et al.
2011) showing the complex situation in different organ systems. As circulating levels of follistatin represent an overall measure of all follistatin-generating tissues further studies are needed to elucidate these complex interacting networks.
Follistatin regulates both, activin A and myostatin (Lee et al.
2010; Vamvini et al.
2013). Elevated expression of activins promotes muscle wasting and cachexia, whereas blocking of activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy (Chen et al.
2014; Lach-Trifilieff et al.
2014). In addition, Chen et al. (
2014) showed that increasing circulating activin A in mice not only promoted the reduction of body weight and muscle mass in a dose-dependent manner, but also reduced muscle function highlighting the therapeutic potential of activin A inhibitors. Therefore, we would have expected a decrease of activin A in the RT and RTS group but instead we detected a small decrease in activin A in CT. However, concerning age-related changes it is still not clear whether activin A levels are influenced by age itself. While some studies have revealed increased circulating activin A levels with age (Baccarelli et al.
2001; Loria et al.
1998), our working group and others did not find any differences between young and old women (Hofmann et al.
2015; Klein et al.
2004). Taking a closer look at the data we found that most of the activin A levels at baseline were below 1 ng/ml while only few subjects (
n = 12) displayed higher levels up to 6 ng/ml. Interestingly, higher levels of activin A at baseline were associated with decreases of skeletal muscle mass between T1 and T3 irrespective of the intervention group hinting to a more catabolic situation in these individuals at the beginning of the intervention and potentially making it more difficult for them to increase muscle mass (Fig.
2b). As activin A function can be inhibited by binding of follistatin to activin A, the activin A-to-follistatin ratio was determined. We observed that the ratio was lowered in the RT group shifting the plasma environment to a more follistatin-dominated one while it was unaffected in the CT group despite lower levels of activin A in this group. This highlights the importance of observing networks of biomarkers, such as the follistatin/activin A/myostatin-axis rather than single ones.
Both representatives of the TGF-β superfamily, myostatin (also known as GDF-8) and GDF-15 were found to be unaffected by the intervention. Because of its distinct impact on fat and muscle mass, several studies have dealt with muscular myostatin expression in context with acute strength exercise (Hulmi et al.
2008; Jensky et al.
2010,
2007) and long-term training (Brooks et al.
2010; Diel et al.
2010; Suetta et al.
2013) in young as well as aged women and men. One interesting though unexpected finding of our study was that myostatin levels at baseline correlated positively with changes in muscle mass. Studies investigating circulating levels of myostatin in response to training interventions are still contradictory which weakens final statements on the role of circulating myostatin in adaptations to resistance training. In this respect it has been shown that 10 weeks of high-intensity resistance exercise in young healthy men leads to a decrease in circulating myostatin (Walker et al.
2004). On the other hand serum myostatin propeptide is not altered in young and healthy men performing strength training for 3 months (Diel et al.
2010), and serum myostatin even increases after a 6-month lifestyle intervention programme in obese children (Ehehalt et al.
2011). Differences in measurement methods, age, training loads and training durations may cause these conflicting results. Another hypothesis was provided by Willboughby (
2004) who suggested that increases in serum levels of the follistatin-like related gene and the concomitant down-regulation of the activin IIb receptor would counteract even increases in myostatin observed after heavy resistance training. Having these aspects in mind we conclude that the beneficial effects of strength training observed for MQ and functional parameters in our study might be due to blocking of activin A and myostatin by enhanced levels of follistatin rather than by lower circulating levels of activin A and myostatin.
Similar to myostatin we could not find any changes in circulating GDF-15 neither in one of the training groups nor in CT over the time of intervention, but GDF-15 levels were negatively associated with MQ of upper extremities at baseline. Additionally, better performance in the chair stand test was negatively associated with changes in muscle mass between T1 and T3 confirming the negative effects of GDF-15 on skeletal muscle (Fig.
3). This is similar to a study of patients undergoing cardiac surgery in which elevated GDF-15 levels were associated with quadriceps muscle atrophy and were elevated after the surgery (Bloch et al.
2013). Traditionally, this biomarker is suggested to reflect the status of cardiac muscle (Sinning et al.
2015) or lung tissue (Mutlu et al.
2015) and we suggest further investigation is needed to elucidate its role in skeletal muscle.
IGF-1 is considered as an important positive regulator of muscle mass which did not change in response to resistance training with or without supplementation. Our data confirm a previous study in older men and women showing positive effects of a 12-week elastic band exercise programme on body composition and physical fitness without improving IGF-1 levels (So et al.
2013). Similarly, IGF-1 was unaffected by low-load resistance exercise with blood flow restriction in older men (Patterson et al.
2013). However, age seems to be a main determinant in the IGF-1 response to exercise training. We have shown that IGF-1 level differ between young and old women (Hofmann et al.
2015), and young men responded to a strength training programme with increased levels of IGF-1 (Takano et al.
2005). There is growing evidence that a chronic inflammatory state suppresses the GH/IGF1 axis (Andreassen et al.
2012; O’Connor et al.
2008; Pass et al.
2009; Strle et al.
2007). According to the ‘inflammageing theory’ elevated levels of proinflammatory cytokines are found with ageing (Schmidt et al.
2011). As we have shown that hs-CRP concentrations in our study population are higher than in young women (Halper et al.
2015), we hypothesize that increased levels of proinflammatory mediators could have blunted an increase in IGF-1 levels.